Metagenomic analyses of the gut microbiota associated with colorectal adenomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiota associated with colorectal adenoma (CRA) and intramucosal colorectal cancer (CRC), building on prior work linking Fusobacterium nucleatum to advanced colorectal carcinoma progression. Researchers used metagenomic analysis of the V3-V4 region of the 16S ribosomal RNA gene to profile bacterial communities from colonoscopy aspirates. The linear discriminant analysis (LDA) effect size (LEfSe) method was applied to detect microbial dysbiosis and identify taxa that differed in abundance between groups.
Who was studied?
The study included 81 Japanese patients undergoing colonoscopy, comprising 47 patients with colorectal adenoma and 24 patients with intramucosal colorectal cancer. An additional 10 healthy subjects served as controls. All samples were derived from colonoscopy aspirates rather than stool, distinguishing the sampling approach from many other gut microbiome studies.
What were the most important findings?
LEfSe analysis revealed significant differences in bacterial abundances between healthy controls and patients with CRA or intramucosal CRC. Notably, Fusobacterium varium, rather than the more commonly implicated F. nucleatum, was found to be statistically more abundant in patients with CRA and intramucosal CRC compared to healthy subjects. This suggests a specific dysbiotic signature involving F. varium is present even at these earlier stages of colorectal neoplasia.
What are the greatest implications of this study?
The findings indicate that F. varium is at least partially involved in the pathogenesis of colorectal adenoma and intramucosal colorectal cancer, expanding the Fusobacterium-CRC association beyond F. nucleatum to an earlier point in disease progression. This raises the possibility that F. varium could serve as a microbial marker for early neoplastic changes in the colon. Further work would be needed to determine whether this association reflects a causal role or a marker of the changing gut environment during adenoma-to-carcinoma progression.